Liver Cancer Center Clinical Trials
Clinical trials are studies that are important for discovering new therapies and treatments for liver cancer. They also seek new ways to detect, diagnose and reduce the chance of developing cancer. The ultimate goal of clinical trials is to improve the lives of our patients. Trials involve collaboration across multiple departments, with researchers involved in design, testing and analysis of these studies.
Orlando Health Cancer Institute Research & Clinical Trials Program focuses on trials designed to assess a wide range of cancer-fighting options. We strive to improve our standards of care and patient outcomes through medications, therapies, genetics, diet and better screening.
Trials also offer our patients an avenue for gaining early access to promising research that may be used to prevent, diagnose and treat liver cancer.
-
Phase I Open-Label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination with an Anti-PD-1 mAb in Patients with Advanced or Metastatic Solid Tumors. +
Phase I Open-Label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination with an Anti-PD-1 mAb in Patients with Advanced or Metastatic Solid Tumors.
Protocol No: 1456-0001
Age Group: Adult
Disease Sites: Eye and Orbit, Lip, Oral Cavity and Pharynx, Pancreas
NCT Id: NCT05155332
Phase: I
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 14732
File Name: UPDATED Subject Eligibility _Screening Checklist_1456-001_Part One (2).docx
URL:
Objective
To determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) for BI 1831169 both as monotherapy and in combination with an anti-PD-1 antibody and to assess the efficacy, safety and tolerability when given via intravenous and intratumoral routes.
-
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy +
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy
Protocol No: 75276617AML3001
Age Group: Adult
Disease Sites: Myeloid and Monocytic Leukemia
NCT Id: NCT06852222
Phase: III
Principal Investigators: Juan Varela MD, PhD
Eligibility Document -
Attachment Id: 16972
File Name: Subject Eligibility _Screening Checklist_JNJ75276617AML3001.docx
URL:
Objective
The primary objective is to determine whether the addition of bleximenib to VEN+AZA significantly improves the dual primary endpoints of CR rate or OS compared with VEN+AZA in participants with ND KMT2Ar or NPM1mAML who are ineligible for intensive chemotherapy
-
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL +
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
Protocol No: A041501
Age Group: Adult
Disease Sites: Leukemia, other
NCT Id: NCT03150693
Phase: III
Principal Investigators: Jose Sarriera, MD
Objective
The main goal of this study is to find out if adding inotuzumab ozogamicin to standard chemotherapy works better than chemotherapy alone for treating young adults with newly diagnosed B-cell acute lymphoblastic leukemia, and to see how safe this combination is.
-
A Randomized, Phase 3 Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01) +
A Randomized, Phase 3 Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)
Protocol No: D702AC00001
Age Group: Adult
Disease Sites: Gastric Disease
NCT Id: NCT06764875
Phase: III
Principal Investigators: Jacobo Hincapie-Echeverri, MD
Objective
To find out if adding the medicine rilvegostomig to trastuzumab deruxtecan and chemotherapy works better and is as safe as the current standard treatment of pembrolizumab with trastuzumab and chemotherapy for people with HER2 positive stomach or GE junction cancer that has spread or cannot be removed.
-
A Phase 2, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma +
A Phase 2, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Protocol No: GO45434
Age Group: Adult
Disease Sites: Non-Hodgkin's Lymphoma
NCT Id: NCT06806033
Phase: II
Principal Investigators: Juan Varela MD, PhD
Eligibility Document -
Attachment Id: 14973
File Name: Subject Eligibility _Screening Checklist_GO45434.docx
URL:
Objective
This study will evaluate the optimization of the CRS profile for the Glofit-GemOx treatment regimen in patients with R/R DLBCL, using optimized regimen of steroids and a revised infusion and monitoring regimen to optimize the CRS profile of this treatment combination.
-
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors +
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors
Protocol No: IDE397-001
Age Group: Adult
Disease Sites: Esophagus, Lung, Melanoma, Skin, Pancreas
NCT Id: NCT04794699
Phase: I
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 7934
File Name: Subject Eligibility Checklist Version 15MAR2024 final.docx
URL:
Objective
To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IDE397 alone and in combination with docetaxel or paclitaxel in adult participants with advanced solid tumors.
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357) +
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)
Protocol No: INCA34176-357
Age Group: Both
Disease Sites: Other Hematopoietic
NCT Id: NCT06585774
Phase: III
Principal Investigators: Juan Varela MD, PhD
Objective
To compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe cGVHD.
-
A Phase 1B Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma (KISIMA-02) +
A Phase 1B Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma (KISIMA-02)
Protocol No: KISIMA-02
Age Group: Adult
Disease Sites: Pancreas
NCT Id: NCT05846516
Phase: I
Principal Investigators: Omar Kayaleh, MD
Eligibility Document -
Attachment Id: 5231
File Name: Subject Eligibility _Screening Checklist KISIMA 02.docx
URL:
Objective
This study is testing a combination of new cancer-fighting drugs to see if they are safe and might help people with a specific type of pancreatic cancer (KRAS-mutated) live longer or delay the return of their cancer.
-
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE;FL-2) +
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE;FL-2)
Protocol No: M22-003
Age Group: Adult
Disease Sites: Non-Hodgkin's Lymphoma
NCT Id: NCT06191744
Phase: III
Principal Investigators: Jose Sarriera, MD
Eligibility Document -
Attachment Id: 6409
File Name: Subject Eligibility _Screening Checklist M22-003_Version 2.0 dated 09Feb2024.docx
URL:
Objective
This study is testing if a new drug combination (epcoritamab with rituximab and lenalidomide) works better than standard chemotherapy for adults with previously untreated follicular lymphoma.
-
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 with or Without Bevacizumab as First-line Treatment of Participants with KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012) +
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 with or Without Bevacizumab as First-line Treatment of Participants with KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)
Protocol No: MK-1084-012
Disease Sites: Anus, Colon, Other Digestive Organ, Rectum
NCT Id: NCT06997497
Phase: III
Principal Investigators: Jacobo Hincapie-Echeverri, MD
Objective
To evaluate the safety and tolerability of treatment with MK-1084, cetuximab, and mFOLFOX6
-
A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis +
A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
Protocol No: ML44719
Age Group: Adult
Disease Sites: Liver
NCT Id: NCT06096779
Phase: II
Principal Investigators: Jacobo Hincapie-Echeverri, MD
Objective
This study is testing a new treatment in people with advanced liver cancer (hepatocellular carcinoma) who also have moderate liver damage. The goal is to see how safe the treatment is and to track any side effects.
-
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors +
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
Protocol No: MRNA-4359-P101
Age Group: Adult
Disease Sites: Lung, Melanoma, Skin
NCT Id: NCT05533697
Phase: I/II
Principal Investigators: Yuanbin Chen, MD
-
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease +
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Protocol No: NRG-GI008
Age Group: Adult
Disease Sites: Colon
NCT Id: NCT05174169
Phase: II/III
Principal Investigators: Omar Kayaleh, MD
Eligibility Document -
Attachment Id: 13913
File Name: NRG-GI008 CIRCULATE NA Subject Eligibility _Step 1-Study Entry Screening Checklist v4.0 08Jul2025.docx
URL:
Objective
This study is testing whether a blood test called ctDNA can help guide chemotherapy after surgery for stage II or III colon cancer. The goal is to see if using this test can safely reduce how many patients need chemotherapy or help give it only to who really need it, based on signs of cancer in the blood.
Request an Appointment
If you have been diagnosed with liver cancer or are experiencing worrying symptoms, our highly specialized team with dedicated patient navigators is ready to evaluate you and develop a treatment plan that’s right for you.
Navigate Your Health
Find a Cancer Physician
Find a Cancer Physician
Meet our doctors who specialize in the full range of cancer care. Our team of experts has experience in a variety of specialty areas. Together, we provide comprehensive evaluation, diagnosis and treatment options.
Learn More
Patient Portal
Patient Portal
If you are a patient at Orlando Health Cancer Institute, our free online patient portal provides an easy and secure way to manage your health information. Reach us from any location at a time that’s convenient for you.
Learn More
Virtual Visit
Virtual Visit
Need to talk with a doctor, but don’t want to leave your home? Try our virtual visit (telehealth) option to connect with a physician from your phone, tablet or computer.
Learn More
ER Wait Times
Sunday, December 14, 2025 3:13 AM
|
|
Wait Time | |
|---|---|---|
| Orlando Health - Health Central Hospital | Directions | 12 min |
| Orlando Health Arnold Palmer Hospital for Children | Directions | 0 min |
| Orlando Health Bayfront Hospital Emergency Room | Directions | 17 min |
| Orlando Health Dr. P. Phillips Hospital | Directions | 4 min |
| Orlando Health Emergency Room - Blue Cedar | Directions | 1 min |
| Orlando Health Emergency Room - Crossroads | Directions | 0 min |
| Orlando Health Emergency Room - Four Corners | Directions | 1 min |
| Orlando Health Emergency Room - Lake Mary | Directions | 14 min |
| Orlando Health Emergency Room - Longwood | Directions | 0 min |
| Orlando Health Emergency Room - Osceola | Directions | 131 min |
| Orlando Health Emergency Room - Pinellas Park | Directions | 1 min |
| Orlando Health Emergency Room - Randal Park | Directions | 0 min |
| Orlando Health Emergency Room - Reunion Village | Directions | 6 min |
| Orlando Health Emergency Room - Waterford Lakes | Directions | 2 min |
| Orlando Health Horizon West Hospital | Directions | 1 min |
| Orlando Health Melbourne Hospital | Directions | 2 min |
| Orlando Health Orlando Regional Medical Center | Directions | 18 min |
| Orlando Health Sebastian River Hospital | Directions | 0 min |
| Orlando Health South Lake Hospital | Directions | 11 min |
| Orlando Health St. Cloud Hospital | Directions | 24 min |